๐
Filspari
sparsentan
Glomerulonephritis, IGA
โ
Authorised
โ
No active alerts
This medicine has no ongoing shortages, safety letters or recalls.
What it's used for
Filspari is indicated for the treatment of adults with primary immunoglobulin A nephropathy (IgAN) with a urine protein excretion > 1.0 g/day (or urine protein-to-creatinine ratio > 0.75 g/g, see section 5.1).
โ ๏ธ Patient safety
No
Official EMA page
https://www.ema.europa.eu/en/medicines/human/EPAR/filspari